Haystack Oncology News Today

Fitch Ratings has affirmed Quest Diagnostics, Inc.s Long-Term Issuer Default Rating , senior unsecured revolving facility and senior unsecured notes at BBB. The Rating Outlook remains...

/PRNewswire/ -- PinkDx, Inc., an early-stage company focused on positively impacting the health of women throughout their life journey, today launched with $40...

Quest Diagnostics Incorporated beats earnings expectations. Reported EPS is $2.04, expectations were $1.86.

Insightful Analysis of Quest Diagnostics Inc's Market Position and Future Prospects

Quest Diagnostics Incorporated (NYSE:DGX) Q4 2023 Earnings Call Transcript February 1, 2024 Quest Diagnostics Incorporated beats earnings expectations. Reported EPS is $2.15, expectations were $2.14. Quest Diagnostics Incorporated isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Quest Diagnostics Fourth […]

Also, are quarterly VC examinations useful to this city's tech world?

BALTIMORE, Jan. 8, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics company, has entered into a collaboration with Alliance Foundation Trials, LLC for research use of Haystack...

/PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nations leading provider of diagnostic information services, today announced that Yuri A. Fesko, M.D., has...

Quest Diagnostics Incorporated (NYSE:DGX) Q3 2023 Earnings Call Transcript October 24, 2023 Quest Diagnostics Incorporated beats earnings expectations. Reported EPS is $2.22, expectations were $2.19. Operator: Welcome to the Quest Diagnostics Third Quarter 2023 Conference Call. At the request of the company, this call is being recorded. The entire contents of the call, including the […]

DGX - Q3 2023 CONFERENCE CALL SCRIPT Tuesday, October 24, 2023, 8:30 am ET [888-455-0391 PASSCODE: 7895081] Conference operator: Welcome to...